SCHEMBL845281

SCHEMBL845281

COc1cccc(CCC(=O)N2CCC[C@H]2C(=O)Nc2ccc(/C=C/c3ccc(NC(=O)[C@@H]4CCCN4C(=O)CCc4cccc(OC)c4)cc3)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
NPSR1 Q6W5P4 4/20 0.52
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
TDP1 Q9NUW8 2/20 0.49
TSHR P16473 1/20 0.48
EP300 Q09472 2/20 0.47
CREBBP Q92793 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
F2 P00734 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL844898 0.91 ALDH1A1 (0.54) ALDH1A1MAPK1HTTCYP2C9CYP2C19
SCHEMBL845157 0.82 ALDH1A1 (0.57) ALDH1A1MAPK1HTTCYP2C9CYP2C19
SCHEMBL13272434 0.80 KDM4E (0.64) ALDH1A1CYP2C9NPSR1MEN1KMT2A
SCHEMBL845373 0.79 ALDH1A1 (0.57) ALDH1A1NPSR1MEN1KMT2ATSHR
SCHEMBL845206 0.78 CYP2C9 (0.52) ALDH1A1MAPK1HTTCYP2C9CYP2C19
SCHEMBL845226 0.77 ALDH1A1 (0.56) ALDH1A1MAPK1HTTCYP2C9CYP2C19
SCHEMBL15116912 0.77 ALDH1A1 (0.56) ALDH1A1MAPK1HTTCYP2C9CYP2C19
SCHEMBL13272444 0.77 ALDH1A1 (0.56) ALDH1A1MAPK1HTTCYP2C9CYP2C19
SCHEMBL845111 0.77 ALDH1A1 (0.56) ALDH1A1MAPK1HTTCYP2C9CYP2C19
SCHEMBL845205 0.77 ALDH1A1 (0.56) ALDH1A1MAPK1HTTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed